On November 20, 2026, the U.S. Food and Drug Administration declined to approve deramiocel, an experimental cell therapy for Duchenne muscular dystrophy. The agency said the evidence in Capricor Therapeutics’ resubmitted application was not sufficient for approval. It also said serious problems in how a key clinical trial was conducted made that study’s data unreliable. FDA statement on deramiocel
For families who had been waiting for the FDA’s decision, the immediate answer is clear: this review did not make deramiocel available as an FDA-approved treatment. What happens next is not yet known.
What the FDA decided
The FDA issued a Complete Response Letter. In plain language, that means the agency finished reviewing the application and cannot approve it in its current form. It is not an approval, and it does not by itself mean the product can never be reconsidered. FDA regulations on Complete Response Letters for biologics
Deramiocel uses cells grown from donated heart tissue. In August, Capricor submitted additional analyses and two years of follow-up from an extension in which participants knew what treatment they were receiving. It also changed its proposed use to focus on arm function. The FDA’s original public advisory committee discussion focused on heart muscle disease in people with Duchenne. The two proposed uses are not the same. The agency considered the additional material in its latest review and still concluded that the evidence did not meet the standard for approval. Capricor’s November corporate update · FDA advisory committee materials
Why the reliability of the evidence mattered
The FDA said its inspection found serious problems in the conduct of HOPE-3. It cited changes made to the analysis plan after the fact without authorization and problems with procedures meant to keep treatment assignments hidden. The FDA concluded the data were unreliable for deciding whether the treatment works and could not be fixed after the fact. The agency also sent Capricor a separate Regulatory Responsibility Letter about the inspection findings and said the company would have a chance to respond. That separate letter does not change the approval decision. FDA statement on deramiocel
Capricor said it stands behind its trials and believes its data support approval. The company said it was reviewing the letter before outlining its next steps and scheduled an investor call for November 23 at 8:30 a.m. ET. The company’s interpretation does not change the FDA’s finding. The public announcements did not establish when, or whether, another application would be filed. Capricor’s November 20 regulatory update
What families can take from this
It is understandable to feel disappointed after waiting for an answer. This decision applies to deramiocel’s application. It does not decide the future of all cell therapy research in Duchenne. The letter does not by itself establish whether ongoing studies or access programs will continue. If you or your child are already enrolled, ask your study team or treating clinician what this means for you. Parent Project Muscular Dystrophy’s guidance for families
For the lead-up to this decision, see our earlier coverage of the extended review.

